These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 7570409)

  • 1. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
    Ulrik CS
    Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].
    Ulrik CS
    Ugeskr Laeger; 1996 Jun; 158(25):3604-7. PubMed ID: 8693619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
    Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B; Markham A
    Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
    Taccola M; Bancalari L; Ghignoni G; Paggiaro PL
    Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.
    Grove A; Lipworth BJ; Reid P; Smith RP; Ramage L; Ingram CG; Jenkins RJ; Winter JH; Dhillon DP
    Thorax; 1996 Jul; 51(7):689-93. PubMed ID: 8882074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
    Nightingale JA; Rogers DF; Barnes PJ
    Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
    Lundback B; Rawlinson DW; Palmer JB
    Thorax; 1993 Feb; 48(2):148-53. PubMed ID: 8493629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
    Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmeterol xinafoate in children on high dose inhaled steroids.
    Russell G; Williams DA; Weller P; Price JF
    Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
    Boyd G
    Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
    Cazzola M; Vinciguerra A; Di Perna F; Matera MG
    Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
    van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
    Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.
    van Noord JA; Schreurs AJ; Mol SJ; Mulder PG
    Thorax; 1999 Mar; 54(3):207-12. PubMed ID: 10325895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.